ONCORUS INC (ONCR) Stock Price, Forecast & Analysis
NASDAQ:ONCR • US68236R1032
ONCR Key Statistics, Chart & Performance
The current stock price of ONCR is 0.1206 USD. In the past month the price decreased by -60.83%. In the past year, price decreased by -91.45%.
ONCR Technical Analysis
ONCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONCR. Both the profitability and financial health of ONCR have multiple concerns.
ONCR Financial Highlights
Over the last trailing twelve months ONCR reported a non-GAAP Earnings per Share(EPS) of -3.49. The EPS decreased by -28.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ONCR Forecast & Estimates
7 analysts have analysed ONCR and the average price target is 5.1 USD. This implies a price increase of 4128.86% is expected in the next year compared to the current price of 0.1206.
ONCR Ownership
ONCR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.14 | 402.079B | ||
| AMGN | AMGEN INC | 16.33 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.43 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.31 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.24 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.55 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.99 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.23 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ONCR
Company Profile
Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. The company is headquartered in Andover, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2020-10-02. The Company’s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The firm intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The firm is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The firm designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.
Company Info
ONCORUS INC
4 Corporate Drive
Andover MASSACHUSETTS 02139 US
CEO: Theodore (Ted) Ashburn
Employees: 64
Phone: 18573206400.0
ONCORUS INC / ONCR FAQ
What does ONCR do?
Oncorus, Inc. engages in the research and development of a viral immunotherapy platform. The company is headquartered in Andover, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2020-10-02. The Company’s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The firm intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The firm is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The firm designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.
What is the stock price of ONCORUS INC today?
The current stock price of ONCR is 0.1206 USD. The price decreased by -8.5% in the last trading session.
What is the dividend status of ONCORUS INC?
ONCR does not pay a dividend.
How is the ChartMill rating for ONCORUS INC?
ONCR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists ONCR stock?
ONCR stock is listed on the Nasdaq exchange.
Can you provide the ownership details for ONCR stock?
You can find the ownership structure of ONCORUS INC (ONCR) on the Ownership tab.